智能胰岛素输送的葡萄糖反应材料:从基于蛋白质的设计到无蛋白质的设计
Suchetan Pal1,2, Tatini Rakshit3, Sunita Saha2
1Department of Bioscience and Biomedical Engineering, Indian Institute of Technology-Bhilai, Durg, 491002, CG India.
ACS materials Au
|March 17, 2025
概括
智能胰岛素输送系统使用对葡萄糖敏感的材料来模仿胰腺. 无蛋白质材料在糖尿病治疗中比较老的基于蛋白质的系统提供了更好的稳定性.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 糖尿病 技术 技术
背景情况:
- 糖尿病管理传统上依赖于外部胰岛素的管理.
- 胰腺通过闭环胰岛素分泌自然调节血糖.
- 适应葡萄糖的材料旨在复制这种自然的反机制.
研究的目的:
- 审查对葡萄糖敏感材料的演变,以实现智能胰岛素输送.
- 为了比较基于蛋白质和无蛋白质的系统.
- 概述该领域的挑战和未来前景.
主要方法:
- 基于蛋白质的系统的审查 (例如,葡萄糖氧化酶,康卡纳瓦林A).
- 分析无蛋白系统 (例如基于酸的水凝,纳米凝,微针).
- 讨论设计原则,葡萄糖/pH敏感性和系统分解.
主要成果:
- 基于蛋白质的系统面临着稳定性,可扩展性和免疫性方面的挑战.
- 没有蛋白质的系统显示出增强的长期稳定性和可存储性.
- 不同的材料设计表现出不同的葡萄糖感应和胰岛素释放机制.
结论:
- 无蛋白质的葡萄糖反应材料代表了智能胰岛素输送的重大进展.
- 需要进一步的研究来克服临床翻译的剩余挑战.
- 这些材料有望改善糖尿病管理和生活质量.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
332
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
332
Insulin Formulations: Types and Delivery
150
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
150
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124


